Get the Stockscreener App
1.27
4.10%
0.05
Nexalin Technology Inc stock is traded at $1.27, with a volume of 188.22K.
It is up +4.10% in the last 24 hours and down -28.25% over the past month.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$1.22
Open:
$1.18
24h Volume:
188.22K
Relative Volume:
1.12
Market Cap:
$23.81M
Revenue:
$128.60K
Net Income/Loss:
$-4.60M
P/E Ratio:
-2.0159
EPS:
-0.63
Net Cash Flow:
$-3.74M
1W Performance:
-29.05%
1M Performance:
-28.25%
6M Performance:
-66.58%
1Y Performance:
+9.48%
1-Day Range:
$1.15
$1.30
1-Week Range:
$1.15
$1.4295
52-Week Range:
$0.53
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
1.27 | 23.81M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Nexalin Technology Inc Stock (NXL) Latest News
Nexalin Technology slides after pricing $5M stock offering - MSN
Nexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 Million - Nasdaq
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - GlobeNewswire
Brain Tech Pioneer Nexalin Secures $5M Funding: 3.85M Shares at $1.30 in Public Offering - Stock Titan
Nexalin Technology Announces Public Offering Agreement - TipRanks
Form 424B4 Nexalin Technology, Inc. - StreetInsider
Nexalin Gains International Traction - ACCESS Newswire
Nexalin Shares Fall After Pricing of $5 Million Public Offering - marketscreener.com
Nexalin Technology (NXL) Announces Public Stock Offering | NXL S - GuruFocus
Nexalin Technology sets public offering at $1.30 per share - Investing.com Australia
Nexalin Prices 3.85 Mln Public Offering At $1.30/shr; Stock Plunges In Pre-market - Nasdaq
Nexalin Technology sets public offering at $1.30 per share By Investing.com - Investing.com India
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewswire
Nexalin Technology Prices $5 Million Public Offering - marketscreener.com
$5M Public Offering: How Nexalin Plans to Advance Revolutionary Brain Stimulation Technology - Stock Titan
SEC Form 424B5 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology, Inc. (NASDAQ:NXL) Shares Acquired by Geode Capital Management LLC - Defense World
SEC Form 424B4 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology (NXL) Seeks FDA Feedback for Gen-2 SYNC Syste - GuruFocus
Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design - marketscreener.com
Nexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive Disorders - Nasdaq
Nexalin Technology Initiates FDA Q-Submission Process for - GlobeNewswire
FDA Fast-Tracks Nexalin Gen-2 SYNC Review for Alzheimer's Treatment | NXL Stock News - Stock Titan
Nexalin Technology (NASDAQ:NXL) Shares Down 0.5% – Time to Sell? - Defense World
International Milestone for Anxiety-Insomnia Neurostim Company - Sleep Review
Nexalin Technology files $50M common stock offering - MSN
Nexalin Technology (NXL) Gains Approval for Clinical Trial in Br - GuruFocus
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewswire
Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia - marketscreener.com
Nexalin's Neurostimulation Device Begins Phase II Trial for Anxiety and Insomnia Treatment in Brazil - Stock Titan
Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More Offerings - marketscreener.com
Nexalin Technology (NXL) Launches Advanced Virtual Clinic for Mi - GuruFocus
Nexalin Technology Announces Launch of Virtual Clinic to Enhance Clinical Research and Patient Care for Mental Health Disorders - Nasdaq
Nexalin Technology Announces Completion of Phases One - GlobeNewswire
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management - TradingView
Nexalin Technology, Inc. Supports Health Tech Investment Act to Enhance Medicare Reimbursement for AI-Enabled Medical Devices - Nasdaq
Nexalin Technology Expresses Strong Support for Health Tech - GlobeNewswire
Medicare May Cover AI Mental Health Devices as Nexalin Backs New Bill | NXL Stock News - Stock Titan
Nexalin Technology appoints new accounting firm By Investing.com - Investing.com Canada
Nexalin Technology appoints new accounting firm - Investing.com
Nexalin secures patent on brain stimulation method for substance use disorders - Yahoo
Nexalin Secures Patent for Intracranial Stimulation Technology - marketscreener.com
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders - The Manila Times
Nexalin Technology Secures USPTO Patent for Deep - GlobeNewswire
Game-Changing Patent: Nexalin's Brain Stimulation Tech Takes On $35B Addiction Treatment Market - Stock Titan
Nexalin begins clinical trial for brain stimulation therapy By Investing.com - Investing.com South Africa
Nexalin begins clinical trial for brain stimulation therapy - Investing.com
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - The Manila Times
Revolutionary Brain Treatment: Nexalin Launches PTSD Trial at UCSD with AI-Powered Home Therapy - Stock Titan
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3 - GlobeNewswire
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 - The Manila Times
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nexalin Technology Inc Stock (NXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
3.10 |
1,000 |
3,100 |
155,793 |
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
2.98 |
1,000 |
2,980 |
154,793 |
| Owens David | Chief Medical Officer |
Jan 28 '25 |
Buy |
2.70 |
1,500 |
4,050 |
153,793 |
| Owens David | Chief Medical Officer |
Jan 13 '25 |
Buy |
2.50 |
2,000 |
5,000 |
151,293 |
| Owens David | Chief Medical Officer |
Jan 23 '25 |
Buy |
2.70 |
1,000 |
2,700 |
152,293 |
| Owens David | Chief Medical Officer |
Oct 28 '24 |
Buy |
2.19 |
500 |
1,095 |
148,293 |
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
| Owens David | Chief Medical Officer |
Jun 28 '24 |
Buy |
1.75 |
1,000 |
1,750 |
146,793 |
| Owens David | Chief Medical Officer |
Jun 18 '24 |
Buy |
0.71 |
1,619 |
1,149 |
145,793 |
| Owens David | Chief Medical Officer |
Jun 10 '24 |
Buy |
0.64 |
3,000 |
1,920 |
144,174 |
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):